-logo-1200x675.png?v=20240521153233&w=240&h=240&zc=2){kind=logo}
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ITCI. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price […]
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ITCI. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price […]
